Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists

Elizabeth Calhoun, Charles L. Bennett, Patti A. Peeples, John R. Lurain, Philip Y. Roland, Jill M. Weinstein, David A. Fishman

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background. We conducted a pilot study to evaluate issues related to chemotherapy-induced toxicities by eliciting assessments of toxicity from women with advanced stage ovarian cancer and gynecologic oncologists. Patients and methods. Fifteen ovarian cancer patients and ten gynecologic oncologists completed the survey exercises. All patients surveyed had received at least six courses of a cisplatin-containing chemotherapy regimen. Results. For both patients and physicians, there was good face validity to the utility exercise as assessments of health states with cisplatin were (1) consistently associated with less favorable assessments than the health state with no toxicity and (2) neurotoxicity was viewed less favorably than either ototoxicity or nephrotoxicity. While the 15 patients as a group viewed health states with toxicity more favorably than physicians (P < 0.05 for each toxicity), patient assessments varied, depending on individual experiences with cisplatin. Physician assessments of toxicity were most similar to those obtained from patients who had not experienced cisplatin toxicity and were less favorable than those elicited from patients who had experienced any toxicity. Conclusions. In deciding upon therapeutic strategies, women with advanced stage ovarian cancer and treating physicians markedly differ in their assessment of the impact of specific toxicities on quality of life.

Original languageEnglish (US)
Pages (from-to)369-375
Number of pages7
JournalGynecologic Oncology
Volume71
Issue number3
DOIs
StatePublished - Dec 1998
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Cisplatin
Physicians
Health
Exercise
Drug Therapy
Oncologists
Reproducibility of Results
Quality of Life

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Calhoun, E., Bennett, C. L., Peeples, P. A., Lurain, J. R., Roland, P. Y., Weinstein, J. M., & Fishman, D. A. (1998). Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists. Gynecologic Oncology, 71(3), 369-375. https://doi.org/10.1006/gyno.1998.5189

Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists. / Calhoun, Elizabeth; Bennett, Charles L.; Peeples, Patti A.; Lurain, John R.; Roland, Philip Y.; Weinstein, Jill M.; Fishman, David A.

In: Gynecologic Oncology, Vol. 71, No. 3, 12.1998, p. 369-375.

Research output: Contribution to journalArticle

Calhoun, E, Bennett, CL, Peeples, PA, Lurain, JR, Roland, PY, Weinstein, JM & Fishman, DA 1998, 'Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists', Gynecologic Oncology, vol. 71, no. 3, pp. 369-375. https://doi.org/10.1006/gyno.1998.5189
Calhoun, Elizabeth ; Bennett, Charles L. ; Peeples, Patti A. ; Lurain, John R. ; Roland, Philip Y. ; Weinstein, Jill M. ; Fishman, David A. / Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists. In: Gynecologic Oncology. 1998 ; Vol. 71, No. 3. pp. 369-375.
@article{01e217e5e58b4550b8d5301e3a721822,
title = "Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists",
abstract = "Background. We conducted a pilot study to evaluate issues related to chemotherapy-induced toxicities by eliciting assessments of toxicity from women with advanced stage ovarian cancer and gynecologic oncologists. Patients and methods. Fifteen ovarian cancer patients and ten gynecologic oncologists completed the survey exercises. All patients surveyed had received at least six courses of a cisplatin-containing chemotherapy regimen. Results. For both patients and physicians, there was good face validity to the utility exercise as assessments of health states with cisplatin were (1) consistently associated with less favorable assessments than the health state with no toxicity and (2) neurotoxicity was viewed less favorably than either ototoxicity or nephrotoxicity. While the 15 patients as a group viewed health states with toxicity more favorably than physicians (P < 0.05 for each toxicity), patient assessments varied, depending on individual experiences with cisplatin. Physician assessments of toxicity were most similar to those obtained from patients who had not experienced cisplatin toxicity and were less favorable than those elicited from patients who had experienced any toxicity. Conclusions. In deciding upon therapeutic strategies, women with advanced stage ovarian cancer and treating physicians markedly differ in their assessment of the impact of specific toxicities on quality of life.",
author = "Elizabeth Calhoun and Bennett, {Charles L.} and Peeples, {Patti A.} and Lurain, {John R.} and Roland, {Philip Y.} and Weinstein, {Jill M.} and Fishman, {David A.}",
year = "1998",
month = "12",
doi = "10.1006/gyno.1998.5189",
language = "English (US)",
volume = "71",
pages = "369--375",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Perceptions of cisplatin-related toxicity among ovarian cancer patients and gynecologic oncologists

AU - Calhoun, Elizabeth

AU - Bennett, Charles L.

AU - Peeples, Patti A.

AU - Lurain, John R.

AU - Roland, Philip Y.

AU - Weinstein, Jill M.

AU - Fishman, David A.

PY - 1998/12

Y1 - 1998/12

N2 - Background. We conducted a pilot study to evaluate issues related to chemotherapy-induced toxicities by eliciting assessments of toxicity from women with advanced stage ovarian cancer and gynecologic oncologists. Patients and methods. Fifteen ovarian cancer patients and ten gynecologic oncologists completed the survey exercises. All patients surveyed had received at least six courses of a cisplatin-containing chemotherapy regimen. Results. For both patients and physicians, there was good face validity to the utility exercise as assessments of health states with cisplatin were (1) consistently associated with less favorable assessments than the health state with no toxicity and (2) neurotoxicity was viewed less favorably than either ototoxicity or nephrotoxicity. While the 15 patients as a group viewed health states with toxicity more favorably than physicians (P < 0.05 for each toxicity), patient assessments varied, depending on individual experiences with cisplatin. Physician assessments of toxicity were most similar to those obtained from patients who had not experienced cisplatin toxicity and were less favorable than those elicited from patients who had experienced any toxicity. Conclusions. In deciding upon therapeutic strategies, women with advanced stage ovarian cancer and treating physicians markedly differ in their assessment of the impact of specific toxicities on quality of life.

AB - Background. We conducted a pilot study to evaluate issues related to chemotherapy-induced toxicities by eliciting assessments of toxicity from women with advanced stage ovarian cancer and gynecologic oncologists. Patients and methods. Fifteen ovarian cancer patients and ten gynecologic oncologists completed the survey exercises. All patients surveyed had received at least six courses of a cisplatin-containing chemotherapy regimen. Results. For both patients and physicians, there was good face validity to the utility exercise as assessments of health states with cisplatin were (1) consistently associated with less favorable assessments than the health state with no toxicity and (2) neurotoxicity was viewed less favorably than either ototoxicity or nephrotoxicity. While the 15 patients as a group viewed health states with toxicity more favorably than physicians (P < 0.05 for each toxicity), patient assessments varied, depending on individual experiences with cisplatin. Physician assessments of toxicity were most similar to those obtained from patients who had not experienced cisplatin toxicity and were less favorable than those elicited from patients who had experienced any toxicity. Conclusions. In deciding upon therapeutic strategies, women with advanced stage ovarian cancer and treating physicians markedly differ in their assessment of the impact of specific toxicities on quality of life.

UR - http://www.scopus.com/inward/record.url?scp=0032408516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032408516&partnerID=8YFLogxK

U2 - 10.1006/gyno.1998.5189

DO - 10.1006/gyno.1998.5189

M3 - Article

C2 - 9887233

AN - SCOPUS:0032408516

VL - 71

SP - 369

EP - 375

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -